Pumpkin seed protein source anti-oxidation and anti-cancer small molecule peptide tablet and preparation method thereof
By screening out active peptides for breast cancer targets from pumpkin seed protein sequences and preparing small molecule peptide tablets, the problems of complicated screening of small molecule peptides in the prior art and poor breast cancer treatment effects are solved, achieving efficient and safe Anti-breast cancer treatment and rehabilitation effects.
Patent Information
- Application Number
- CN202410945009.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-15
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing small molecule peptide screening methods are cumbersome, difficult to produce on a large scale, and the probability of specific biological activity is low, making it difficult to effectively inhibit the proliferation and apoptosis of breast cancer cells.
By obtaining the pumpkin seed protein sequence, gastrointestinal digestion simulation was carried out, and active peptides with inhibitory potential for oxidative stress and breast cancer targets were screened using online databases and molecular docking methods, and small molecules were prepared by Fmoc solid-phase synthesis method. Peptide tablets, combined with antioxidants to improve anticancer effects.
Improve the in-depth development and application efficiency of small molecule peptides, significantly enhance the treatment effect on breast cancer, has low side effects and high safety, is suitable for personalized treatment and cancer rehabilitation of different patients, simplifies the production process, and is convenient for Large-scale production.
Smart Images

Figure CN118903375A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and particularly relates to a pumpkin seed protein source antioxidant and anticancer small molecule peptide tablet and a preparation method thereof. Background Art
[0002] Pumpkin (scientific name: Cucurbitapepo), also known as pumpkin, rice melon, and vegetable melon, is a plant of the genus Cucurbitaceae, an annual vine. Pumpkin is an important vegetable and food crop. Its seeds are rich in high-quality protein, have high nutritional value, are easy to digest and absorb, and have an amino acid composition close to that of body tissue protein. Therefore, it has attracted much attention from scholars in recent years. At the same time, pumpkin seed protein also has biological activities such as anti-cancer, anti-cancer, anti-bacterial, anti-viral, anti-diabetic and anti-hypertensive effects, and its application prospects in the medical field are very broad.
[0003] With the development of molecular biology, more and more evidence shows that active peptides can be directly absorbed by the human body and participate in a variety of biological activities, such as cell apoptosis, cell growth, immune response, etc. Active peptides have the characteristics of small molecular weight, simple structure, and high biological activity, and are considered to have great medical and nutritional value.
[0004] Small molecule peptides are widely used in the medical field and can be used to treat a variety of diseases, such as diabetes, inflammation and various types of cancer. Small molecule peptides can also be used in the field of antibacterial and antiviral. By interacting with viral surface antigens, they affect the mutual recognition and binding between viruses and host cells, achieving antiviral effects. Small molecule peptides can also improve cardiovascular function, and have the effects of lowering blood cholesterol, lowering blood pressure, dilating blood vessels, and improving myocardial ischemia. Small molecule peptides can also promote the body's nutrient absorption, promote bone development, provide energy to the body, resist fatigue, and have a variety of health benefits. Most importantly, small molecule peptides can also regulate immune function, enhance the body's immune activity, effectively inhibit the proliferation of tumor cells and promote tumor cell apoptosis, and prevent tumor cells from spreading to surrounding tissues, which is of great significance for the treatment and prevention of cancer.
[0005] For the screening of small molecule peptides, the steps of "cell test screening-structure identification-animal test verification" are currently mostly used. This method includes: first obtaining a large number of small molecule peptides, screening through cell tests to obtain small molecule peptides with biological activity, structural identification of the obtained small molecule peptides, and verifying the biological activity of the small molecule peptides through animal tests. This method has cumbersome steps, the probability of screening out small molecule peptides with specific biological activity is low, and it is difficult to produce on a large scale. Summary of the invention
[0006] In view of the problems and shortcomings of the above-mentioned prior art, the purpose of the present invention is to provide a pumpkin seed protein source antioxidant and anti-cancer small molecule peptide tablet and a preparation method thereof. The small molecule peptide tablet prepared by the present invention has excellent antioxidant and anti-breast cancer activity.
[0007] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows:
[0008] A method for preparing pumpkin seed protein-derived antioxidant and anticancer small molecule peptide tablets comprises the following steps:
[0009] S1. Pumpkin seed protein sequence acquisition: The pumpkin seed protein sequence was obtained from Uniprot;
[0010] S2. Submit the pumpkin seed protein sequence obtained in step S1 to an online processing tool, select pepsin and trypsin to hydrolyze the pumpkin seed protein, and obtain the active peptide sequence after gastrointestinal digestion;
[0011] S3, using online databases to predict the safety of the peptide sequences obtained in S2;
[0012] S4. Use molecular docking methods to screen active peptides with inhibitory potential on oxidative stress and breast cancer related targets;
[0013] S5. Synthesis of small molecule peptides;
[0014] S6. Preparation of small molecule peptide tablets.
[0015] Preferably, the pumpkin seed protein sequence used in step S1 is as follows:
[0016] Q39649, 2S seed storage albumin, URL https: / / www.uniprot.org / uniprotkb / Q39649 / entry; P13744, 11S seed globulin β subunit, URL https: / / www.uniprot.org / uniprotkb / P13744 / entry; A0A6J1K8H1, 11S seed storage globulin, URL https: / / www.uniprot.org / uniprotkb / A0A6J1K8H1 / entry; A0A6J1I6Z1, seed biotin protein SBP65, URL https: / / www.uniprot.org / uni protkb / A0A6J1I6Z1 / entry; A0A6J1JDB2, 12S seed storage protein-CRD, https: / / www.uniprot.org / uniprotkb / A0A6J1I6Z1 / entry; A0A6J1IU23, Vicilin-like seed storage protein At2g18540, https: / / www.uniprot.org / uniprotkb / P13744 / entry; A0A6J1JBK8, 2S sulfur-rich seed storage protein, https: / / www.uniprot.org / uniprotkb / A0A6J1JBK8 / entry.
[0017] Preferably, the website of the online processing tool in S2 is: http: / / web.expasy.org / peptide_cutter / .
[0018] Preferably, in step S3, PeptideRanker, Toxinpred and Innovagen are used to predict the potential activity, toxicity, hydrophilicity, hydrophobicity, charge and solubility of the polypeptide sequence obtained in S2.
[0019] Preferably, PeptideRanker (http: / / distilldeep.ucd.ie / Peptide Ranker / ) is used to predict the potential activity of peptides; Toxinpred (http: / / www.imtech.res.in / raghava / toxinpred / ) is used to predict the toxicity, hydrophobicity, hydrophilicity, and charge of peptides; and Innovagen (http: / / www.innovagen.com / proteomics-tools) is used to predict the solubility of peptides.
[0020] Preferably, in S4, a molecular docking method is used to screen active peptides with inhibitory potential on oxidative stress and breast cancer related targets, comprising the following steps:
[0021] (1) Acquisition of 3D structures: The 3D structures of TP53, PHGDH, Caspase3, and Keap1 were obtained from the RCSB database (http: / / www.rcsb.org / pdb);
[0022] (2) Construction of active peptide structure: Use ChemDraw and Chem3D to construct active peptide structure;
[0023] (3) Molecular docking: After removing the ligands and water molecules from TP53, PHGDH, Caspase3, and Keap1 in step (1), nonpolar hydrogen and Gaussian charges were added together with the peptide sequence obtained in S2, and semi-flexible molecular docking of the peptide with TP53, the peptide with PHGDH, the peptide with Caspase3, and the peptide with Keap1 was performed using AutoDock 4.2 software;
[0024] (4) After molecular docking, active peptides that showed the best binding to oxidative stress and breast cancer-related targets were screened based on the binding energy results.
[0025] Further preferably, the TP53 is the tumor protein p53; PHGDH is phosphoglycerate dehydrogenase; Caspase3 is caspase 3; and Keap1 is a cytoplasmic adaptor protein.
[0026] Preferably, the active peptides showing the strongest binding to TP53 are YPSPPY, FPF, ISTANY, IIV, IPQN, VCPPL, CTAIR, VVPR, QPR, and IIPQN;
[0027] The active peptides that showed the strongest binding to PHGDH were GIENPW, IIPQN, QGSEVW, GQQER, VNAPQL, MPHPCK, DDGSE, TPPPGY, QIVQR, and TIRPK;
[0028] The active peptides that showed the strongest binding to Caspase3 were GVEEW, EW, EY, DDGSE, DF, EEA, NVGPE, EEL, DEEER, and PDIH.
[0029] Further preferably, the active peptides that tightly bind to TP53, PHGDH, and Caspase3 and have strong anti-cancer activity are YPSPPY, FPF, ISTANY, IIV, GIENPW, IIPQN, QGSEVW, GVEEW, EW, and EY.
[0030] Preferably, the active peptides with strong antioxidant activity that show the strongest binding to Keap1 are YPSPPY, QIVQR, QGSEVW, VNAPQL, VQVVDN, IIPQN, QGQNDR, TPPPGY, TPPPGF, and GIENPW.
[0031] Further preferred active peptides having both high anticancer activity and high antioxidant activity are YPSPPY, QGSEVW, VNAPQL, VQVVDN, IIPQN, TPPPGY, TPPPGF, GIENPW, ISTANY, AQDPVR, and VCPPL.
[0032] Preferably, in S5, Shanghai Kepeptide Biotechnology Co., Ltd. uses the Fmoc solid phase synthesis method to synthesize the active peptides screened in step S4 into small molecule peptides.
[0033] Preferably, the synthetic small molecule peptides that show the strongest binding to TP53 are YPSPPY, FPF, ISTANY, IIV, IPQN, VCPPL, CTAIR, VVPR, QPR, and IIPQN.
[0034] The small peptides that showed the strongest binding to PHGDH were GIENPW, IIPQN, QGSEVW, GQQER, VNAPQL, MPHPCK, DDGSE, TPPPGY, QIVQR, and TIRPK;
[0035] The small molecule peptides that showed the strongest binding to Caspase3 were GVEEW, EW, EY, DDGSE, DF, EEA, NVGPE, EEL, DEEER, and PDIH.
[0036] Further preferred small molecule peptides that tightly bind to TP53, PHGDH, and Caspase3 and have strong anti-cancer activity are YPSPPY, FPF, ISTANY, IIV, GIENPW, IIPQN, QGSEVW, GVEEW, EW, and EY.
[0037] Preferably, the small molecule peptides with strong antioxidant properties that show the strongest binding to Keap1 are YPSPPY, QIVQR, QGSEVW, VNAPQL, VQVVDN, IIPQN, QGQNDR, TPPPGY, TPPPGF, and GIENPW.
[0038] Further preferred small molecule peptides with both high anticancer activity and high antioxidant activity are YPSPPY, QGSEVW, VNAPQL, VQVVDN, IIPQN, TPPPGY, TPPPGF, GIENPW, ISTANY, AQDPVR, and VCPPL.
[0039] The structural formula of the above small molecule peptide is as follows:
[0040]
[0041]
[0042] Preferably, step S6 is to mix one or more of the small molecule peptides synthesized in S5 with epigallocatechin gallate, ginsenoside, rutin, quercetin and dextrin.
[0043] The present invention also provides pumpkin seed protein source antioxidant and anticancer small molecule peptide tablets prepared by the preparation method.
[0044] Preferably, the dosage form of the pharmaceutical agent is a tablet, which is prepared by mixing the above-mentioned substances, placing the mixture in a hopper, using a tablet press to tablet the mixture in the hopper, and taking out the tablets after tableting and packaging them.
[0045] Preferably, the tablet weighs 0.2-0.4 g.
[0046] The invention discloses a pumpkin seed protein source antioxidant and anticancer small molecule peptide tablet, which comprises the following components: 0-1 part each of YPSPPY, FPF, IIV, QGSEVW, GVEEW, EW, EY, QIVQR, QGQNDR, VNAPQL, VQVVDN, IIPQN, TPPPGY, TPPPGF, GIENPW, ISTANY, AQDPVR and VCPPL, 1-5 parts of epigallocatechin gallate, 1-5 parts of ginsenoside, 1-5 parts of rutin, 1-5 parts of quercetin and 4-20 parts of dextrin.
[0047] Compared with the prior art, the present invention has the following beneficial effects:
[0048] 1. The present invention provides a pumpkin seed protein-derived antioxidant and anti-cancer small molecule peptide tablet and a preparation method thereof. The tablet has high efficiency and specificity, enhances the in-depth development of small molecule peptides and their application in the medical field, and exhibits obvious anti-breast cancer effects.
[0049] 2. The pumpkin seed protein-derived anti-breast cancer small molecule peptide tablets of the present invention can be administered in different formulations according to the patient's physical condition. Patients undergoing treatment can be administered tablets with better anti-cancer effects, while patients recovering from cancer can be administered tablets with better antioxidant effects.
[0050] 3. The pumpkin seed protein-derived anti-breast cancer small molecule peptide tablets of the present invention have low side effects and high safety, making them an ideal choice for adjuvant treatment of breast cancer. This tablet can not only assist the main treatment plan and improve the treatment effect, but also effectively alleviate various side effects caused by breast cancer, such as inflammation and oxidative stress, thereby improving the quality of life of patients. In addition, the preparation process of the tablet is simple and easy to mass produce, which is conducive to its wide promotion and application in the medical market.
[0051] The technical solution of the present invention is further described in detail below through the accompanying drawings and embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] Figure 1 This is a statistical chart of the effect of the pumpkin seed protein source antioxidant anticancer small molecule peptide tablets provided in Examples 1-4 on the free radical scavenging rate, wherein: Figure 1 a in is the effect diagram of Example 1-4 on DPPH free radical scavenging rate, Figure 1 b is the effect diagram of Examples 1-4 on the ABTS free radical scavenging rate;
[0053] Figure 2 This is a statistical chart of the effects of the pumpkin seed protein source antioxidant and anticancer small molecule peptide tablets provided in the control group and Examples 1-4 on cell survival rate, wherein: Figure 2 a in the figure is the effect of Example 1-4 on the survival rate of MCF-7 cells, Figure 2 b is the effect of Example 1-4 on the survival rate of SK-BR-3 cells. Figure 2 c in the figure is the effect of Example 1-4 on the survival rate of HCC-1937 cells;
[0054] Figure 3 This is a statistical chart of the effects of the pumpkin seed protein source antioxidant and anticancer small molecule peptide tablets provided in the control group and Examples 1-4 on cell migration rate, wherein: Figure 3 a in the figure is the effect of Example 1-4 on the migration rate of MCF-7 cells. Figure 3 b in the figure is the effect of Example 1-4 on the migration rate of SK-BR-3 cells. Figure 3 Figure c is the effect of Example 1-4 on the migration rate of HCC-1937 cells. DETAILED DESCRIPTION
[0055] The technical solution of the present invention is further described below through the accompanying drawings and embodiments.
[0056] Unless otherwise defined, technical or scientific terms used in the present invention shall have the common meanings understood by one having ordinary skills in the field to which the present invention belongs.
[0057] Example 1 This example provides a pumpkin seed protein source antioxidant anticancer small molecule peptide tablet, comprising the following steps:
[0058] S1. Pumpkin seed protein sequence acquisition: The pumpkin seed protein sequence was obtained from Uniprot. The protein sequence is as follows:
[0059] Q39649, 2S seed storage albumin, URL https: / / www.uniprot.org / uniprotkb / Q39649 / entry; P13744, 11S seed globulin β subunit, URL https: / / www.uniprot.org / uniprotkb / P13744 / entry; A0A6J1K8H1, 11S seed storage globulin, URL https: / / www.uniprot.org / uniprotkb / A0A6J1K8H1 / entry; A0A6J1I6Z1, seed biotin protein SBP65, URL https: / / www.uniprot.org / uni protkb / A0A6J1I6Z1 / entry; A0A6J1JDB2, 12S seed storage protein-CRD, https: / / www.uniprot.org / uniprotkb / A0A6J1I6Z1 / entry; A0A6J1IU23, Vicilin-like seed storage protein At2g18540, https: / / www.uniprot.org / uniprotkb / P13744 / entry; A0A6J1JBK8, 2S sulfur-rich seed storage protein, https: / / www.uniprot.org / uniprotkb / A0A6J1JBK8 / entry.
[0060] S2. Submit the pumpkin seed protein sequence obtained in step S1 to http: / / web.expasy.org / peptide_cutter / , select pepsin and trypsin to hydrolyze the pumpkin seed protein, and obtain the active peptide sequence of the pumpkin seed protein after gastrointestinal digestion;
[0061] S3. Safety prediction of the peptide sequences obtained in S2 was performed using online databases: PeptideRanker (http: / / distilldeep.ucd.ie / Peptide Ranker / ) was used to predict the potential activity of peptides; Toxinpred (http: / / www.imtech.res.in / raghava / toxinpred / ) was used to predict the toxicity, hydrophobicity, hydrophilicity, and charge of peptides; Innovagen (http: / / www.innovagen.com / proteomics-tools) was used to predict the solubility of peptides. The screening results are shown in Table 1.
[0062] S4. Using molecular docking method, active peptides with inhibitory potential on oxidative stress and breast cancer related targets were screened, including the following steps:
[0063] (1) Acquisition of 3D structures: The 3D structures of TP53, PHGDH, Caspase3, and Keap1 were obtained from the RCSB database (http: / / www.rcsb.org / pdb);
[0064] (2) Construction of active peptide structure: Use ChemDraw and Chem3D to construct active peptide structure;
[0065] (3) Molecular docking: After removing the ligands and water molecules from TP53, PHGDH, Caspase3, and Keap1 in step (1), non-polar hydrogen and Gaussian charges were added to them together with the peptide sequence obtained in S2, and semi-flexible molecular docking of the peptide with TP53, the peptide with PHGDH, the peptide with Caspase3, and the peptide with Keap1 was performed using AutoDock 4.2 software;
[0066] (4) After molecular docking, the active peptides YPSPPY, QGSEVW, VNAPQL, VQVVDN, IIPQN, TPPPGY, TPPPGF, GIENPW, ISTANY, AQDPVR, and VCPPL were screened out based on the binding energy results.
[0067] S5. Shanghai Kepeptide Biotechnology Co., Ltd. uses the Fmoc solid phase synthesis method to synthesize the active peptides screened in step S4 into small molecule peptides to obtain YPSPPY, QGSEVW, VNAPQL, VQVVDN, IIPQN, TPPPGY, TPPPGF, GIENPW, ISTANY, AQDPVR, and VCPPL small molecule peptides.
[0068] S6. Preparation of small molecule peptide tablets: Mix 1 part of the above YPSPPY, QGSEVW, VNAPQL, VQVVDN, IIPQN, TPPPGY, TPPPGF, GIENPW, ISTANY, AQDPVR, and VCPPL with 3 parts of epigallocatechin gallate, 3 parts of ginsenosides, 3 parts of rutin, 3 parts of quercetin, and 5 parts of dextrin, place in a hopper, and use a tablet press to tablet the mixture in the hopper. Take out the tablets after tableting and package them. The weight of the tablets is 0.2 g.
[0069] Example 2 This example provides a pumpkin seed protein source antioxidant anticancer small molecule peptide tablet, comprising the following steps:
[0070] S1. Obtaining pumpkin seed protein sequence: Obtain pumpkin seed protein sequence from Uniprot, which is the same as the protein sequence obtained in step S1 of Example 1;
[0071] S2. Submit the pumpkin seed protein sequence obtained in step S1 to http: / / web.expasy.org / peptide_cutter / , select pepsin and trypsin to hydrolyze the pumpkin seed protein, and obtain the active peptide sequence of the pumpkin seed protein after gastrointestinal digestion;
[0072] S3. Safety prediction of the peptide sequences obtained in S2 was performed using online databases: PeptideRanker (http: / / distilldeep.ucd.ie / Peptide Ranker / ) was used to predict the potential activity of peptides; Toxinpred (http: / / www.imtech.res.in / raghava / toxinpred / ) was used to predict the toxicity, hydrophobicity, hydrophilicity, and charge of peptides; Innovagen (http: / / www.innovagen.com / proteomics-tools) was used to predict the solubility of peptides. The screening results are shown in Table 1.
[0073] S4. Using molecular docking method, active peptides with inhibitory potential on oxidative stress and breast cancer related targets were screened, including the following steps:
[0074] (1) Acquisition of 3D structures: The 3D structures of TP53, PHGDH, Caspase3, and Keap1 were obtained from the RCSB database (http: / / www.rcsb.org / pdb);
[0075] (2) Construction of active peptide structure: Use ChemDraw and Chem3D to construct active peptide structure;
[0076] (3) Molecular docking: After removing the ligands and water molecules from TP53, PHGDH, Caspase3, and Keap1 in step (1), non-polar hydrogen and Gaussian charges were added to them together with the peptide sequence obtained in S2, and semi-flexible molecular docking of the peptide with TP53, the peptide with PHGDH, the peptide with Caspase3, and the peptide with Keap1 was performed using AutoDock 4.2 software;
[0077] (4) After molecular docking, the active peptides YPSPPY, FPF, ISTANY, IIV, GIENPW, IIPQN, QGSEVW, GVEEW, EW, and EY were screened out based on the binding energy results.
[0078] S5. Shanghai Kepeptide Biotechnology Co., Ltd. uses the Fmoc solid phase synthesis method to synthesize the active peptides screened in step S4 into small molecule peptides to obtain YPSPPY, FPF, ISTANY, IIV, GIENPW, IIPQN, QGSEVW, GVEEW, EW, and EY small molecule peptides.
[0079] S6. Preparation of small molecule peptide tablets: Mix 1 part of the above YPSPPY, FPF, ISTANY, IIV, GIENPW, IIPQN, QGSEVW, GVEEW, EW, and EY with 3 parts of epigallocatechin gallate, 3 parts of ginsenosides, 3 parts of rutin, 3 parts of quercetin, and 5 parts of dextrin, place in a hopper, and use a tablet press to tablet the mixture in the hopper. Take out the tablets after tableting and package them. The weight of the tablets is 0.2 g.
[0080] Example 3 This example provides a pumpkin seed protein source antioxidant anti-cancer small molecule peptide tablet, comprising the following steps:
[0081] S1. Obtaining pumpkin seed protein sequence: Obtain pumpkin seed protein sequence from Uniprot, which is the same as the protein sequence obtained in step S1 of Example 1;
[0082] S2. Submit the pumpkin seed protein sequence obtained in step S1 to http: / / web.expasy.org / peptide_cutter / , select pepsin and trypsin to hydrolyze the pumpkin seed protein, and obtain the active peptide sequence of the pumpkin seed protein after gastrointestinal digestion;
[0083] S3. Safety prediction of the peptide sequences obtained in S2 was performed using online databases: PeptideRanker (http: / / distilldeep.ucd.ie / Peptide Ranker / ) was used to predict the potential activity of peptides; Toxinpred (http: / / www.imtech.res.in / raghava / toxinpred / ) was used to predict the toxicity, hydrophobicity, hydrophilicity, and charge of peptides; Innovagen (http: / / www.innovagen.com / proteomics-tools) was used to predict the solubility of peptides. The screening results are shown in Table 1.
[0084] S4. Using molecular docking method, active peptides with inhibitory potential on oxidative stress and breast cancer related targets were screened, including the following steps:
[0085] (1) Acquisition of 3D structures: The 3D structures of TP53, PHGDH, Caspase3, and Keap1 were obtained from the RCSB database (http: / / www.rcsb.org / pdb);
[0086] (2) Construction of active peptide structure: Use ChemDraw and Chem3D to construct active peptide structure;
[0087] (3) Molecular docking: After removing the ligands and water molecules from TP53, PHGDH, Caspase3, and Keap1 in step (1), non-polar hydrogen and Gaussian charges were added to them together with the peptide sequence obtained in S2, and semi-flexible molecular docking of the peptide with TP53, the peptide with PHGDH, the peptide with Caspase3, and the peptide with Keap1 was performed using AutoDock 4.2 software;
[0088] (4) After molecular docking, the active peptides YPSPPY, QIVQR, QGSEVW, VNAPQL, VQVVDN, IIPQN, QGQNDR, TPPPGY, TPPPGF, and GIENPW were screened out based on the binding energy results.
[0089] S5. Shanghai Kepeptide Biotechnology Co., Ltd. uses the Fmoc solid phase synthesis method to synthesize the active peptides screened in step S4 into small molecule peptides to obtain YPSPPY, QIVQR, QGSEVW, VNAPQL, VQVVDN, IIPQN, QGQNDR, TPPPGY, TPPPGF, and GIENPW small molecule peptides.
[0090] S6. Preparation of small molecule peptide tablets: Mix 1 part of the above YPSPPY, QIVQR, QGSEVW, VNAPQL, VQVVDN, IIPQN, QGQNDR, TPPPGY, TPPPGF, GIENPW with 3 parts of epigallocatechin gallate, 3 parts of ginsenosides, 3 parts of rutin, 3 parts of quercetin, and 5 parts of dextrin, place in a hopper, and use a tablet press to tablet the mixture in the hopper. Take out the tablets after tableting and package them. The weight of the tablets is 0.2 g.
[0091] Example 4 This example provides a pumpkin seed protein source antioxidant anticancer small molecule peptide tablet, comprising the following steps:
[0092] S1. Obtaining pumpkin seed protein sequence: Obtain pumpkin seed protein sequence from Uniprot, which is the same as the protein sequence obtained in step S1 of Example 1;
[0093] S2. Submit the pumpkin seed protein sequence obtained in step S1 to http: / / web.expasy.org / peptide_cutter / , select pepsin and trypsin to hydrolyze the pumpkin seed protein, and obtain the active peptide sequence of the pumpkin seed protein after gastrointestinal digestion;
[0094] S3. Safety prediction of the peptide sequences obtained in S2 was performed using online databases: PeptideRanker (http: / / distilldeep.ucd.ie / Peptide Ranker / ) was used to predict the potential activity of peptides; Toxinpred (http: / / www.imtech.res.in / raghava / toxinpred / ) was used to predict the toxicity, hydrophobicity, hydrophilicity, and charge of peptides; Innovagen (http: / / www.innovagen.com / proteomics-tools) was used to predict the solubility of peptides. The screening results are shown in Table 1.
[0095] S4. Using molecular docking method, active peptides with inhibitory potential on oxidative stress and breast cancer related targets were screened, including the following steps:
[0096] (1) Acquisition of 3D structures: The 3D structures of TP53, PHGDH, Caspase3, and Keap1 were obtained from the RCSB database (http: / / www.rcsb.org / pdb);
[0097] (2) Construction of active peptide structure: Use ChemDraw and Chem3D to construct active peptide structure;
[0098] (3) Molecular docking: After removing the ligands and water molecules from TP53, PHGDH, Caspase3, and Keap1 in step (1), non-polar hydrogen and Gaussian charges were added to them together with the peptide sequence obtained in S2, and semi-flexible molecular docking of the peptide with TP53, the peptide with PHGDH, the peptide with Caspase3, and the peptide with Keap1 was performed using AutoDock 4.2 software;
[0099] (4) After molecular docking, the active peptides YPSPPY, QIVQR, QGSEVW, VNAPQL, VQVVDN, FPF, GIENPW, IIPQN, GVEEW, and EW were screened out based on the binding energy results.
[0100] S5. Shanghai Kepeptide Biotechnology Co., Ltd. uses the Fmoc solid phase synthesis method to synthesize the active peptides screened in step S4 into small molecule peptides to obtain YPSPPY, QIVQR, QGSEVW, VNAPQL, VQVVDN, FPF, GIENPW, IIPQN, GVEEW, and EW small molecule peptides.
[0101] S6. Preparation of small molecule peptide tablets: Mix 1 part of the above YPSPPY, QIVQR, QGSEVW, VNAPQL, VQVVDN, FPF, GIENPW, IIPQN, GVEEW, and EW with 3 parts of epigallocatechin gallate, 3 parts of ginsenosides, 3 parts of rutin, 3 parts of quercetin, and 5 parts of dextrin, put them in a hopper, and use a tablet press to tablet the mixture in the hopper. Take out the tablets after tableting and package them. The weight of the tablets is 0.2 g.
[0102] Table 1 Prediction of active peptide properties
[0103]
[0104]
[0105]
[0106]
[0107]
[0108]
[0109]
[0110] Table 2 Binding energy of active peptides to oxidative stress and cancer target proteins
[0111]
[0112]
[0113]
[0114]
[0115] The effects of the tablets provided in the above embodiments were verified by the following tests:
[0116] 1. To verify the scavenging rate of DPPH and ABTS free radicals in Examples 1-4, the test scheme is as follows: DPPH: Use 80% methanol to dissolve DPPH powder and prepare a 50uM DPPH reaction solution, which is stored in the dark. Add 50uL of sample to each well of a 96-well plate, then add 200uL of DPPH reaction solution, place in the dark to react for 30min, and use an enzyme marker to detect the OD value at 520nm. Set up 6 parallel groups for each sample and take the average value. The calculation method for DPPH scavenging ability is as follows:
[0117]
[0118] Wherein: As-experimental group; Ac-control group; Ab-blank group.
[0119] ABTS: Use distilled water to dissolve ABTS powder and prepare it into an ABTS solution system with a concentration of 7mmol / L. Use distilled water to dissolve potassium persulfate and prepare it into a potassium persulfate solution system with a concentration of 2.45mmol. Mix the ABTS solution and potassium persulfate solution in a 1:1 ratio and place them in a dark place at room temperature for 12-16 hours to form an ABTS+· stock solution. Use 0.1M phosphate buffer to dilute the ABTS+· stock solution to the ABTS+· working solution, and the OD value detected at 734nm is 0.70±0.02. Add 20uL of sample to each well of a 96-well plate, then add 180uL of ABTS+· working solution, place it in the dark for 5min, and detect the OD value at 734nm with an enzyme reader. Set up 6 parallel groups for each sample and take the average value. The calculation method of ABTS+· free radical scavenging ability is as follows:
[0120]
[0121] Where: As-experimental group; Ac-control group; Ab-blank group, the results are shown in Figure 1 .
[0122] Depend on Figure 1It can be seen that the small molecule peptide tablets prepared in Example 1 can scavenge 72.02% of DPPH free radicals and 98.01% of ABTS+· free radicals; the small molecule peptide tablets prepared in Example 2 can scavenge 34.12% of DPPH free radicals and 67.17% of ABTS+· free radicals; the small molecule peptide tablets provided in Example 3 can scavenge 94.29% of DPPH free radicals and 97.12% of ABTS+· free radicals; the small molecule peptide tablets prepared in Example 4 can scavenge 63.75% of DPPH free radicals and 90.44% of ABTS+· free radicals.
[0123] 2. To verify the effects of Examples 1-4 on the survival rates of MCF-7, SK-BR-3, and HCC-1937 cells, the experimental protocol was as follows: MCF-7, SK-BR-3, and HCC-1937 cells were cultured in a high-glucose formula culture medium supplemented with 10% (v / v) fetal bovine serum and 1% (v / v) penicillin-streptomycin. The culture temperature was 37°C and the carbon dioxide concentration was 5%.
[0124] CCK-8 assay: The CCK-8 assay was used to detect the viability of breast cancer cells. Each breast cancer cell line (6 independent replicates) in the logarithmic growth phase was cultured at 5×10 3 The cells were inoculated into 96-well plates at a density of 10 cells / well and then incubated overnight at 37°C. 2.0 mg / mL of Examples 1-4 were added to the cell culture medium and treated for 24 hours, with PBS as a control. Then 10 uL of CCK-8 solution reagent was added to each well and incubated for further 1 hour. The absorbance of the resulting solution was recorded at 450 nm using an ELISA reader (Varioskan Flash 2.4, Thermo Fisher Scientific, USA). Cell viability was expressed as a percentage of the control group. The results are shown in Figure 2 .
[0125] Compared with the control group, the small molecule peptide tablets prepared in Example 1 reduced the survival rates of MCF-7, SK-BR-3, and HCC-1937 cells to 7.67%, 12.68%, and 6.12%, respectively. The small molecule peptide tablets prepared in Example 2 reduced the survival rates of MCF-7, SK-BR-3, and HCC-1937 cells to 5.24%, 9.51%, and 4.28%, respectively. The small molecule peptide tablets prepared in Example 3 reduced the survival rates of MCF-7, SK-BR-3, and HCC-1937 cells to 22.66%, 28.54%, and 16.61%, respectively. The small molecule peptide tablets prepared in Example 4 reduced the survival rates of MCF-7, SK-BR-3, and HCC-1937 cells to 14.43%, 15.48%, and 7.99%, respectively.
[0126] 3. To verify the effect of Examples 1-4 on the migration rate of MCF-7, SK-BR-3 and HCC-1937 cells, the experimental scheme is as follows: MCF-7, SK-BR-3 and HCC-1937 cells were plated on a 6-well plate at 5×10 4 The cells were cultured at a density of 10 cells / well for 48 h. After reaching a density of 80%, the culture medium was aspirated, the cell monolayer was scraped with a 10 uL sterile pipette tip, and then gently washed with PBS to remove cell debris. Then, the cells were incubated with Examples 1-4, respectively, and their migration along the injury line was observed under a microscope. Cell images (5x magnification) were captured after 0 h, 24 h, and 48 h of incubation in Examples 1 to 4, and analyzed using ImageJ software (Maryland, USA). The results are shown in Figure 3 .
[0127] Compared with the control group, the small molecule peptide tablets prepared in Example 1 can reduce the migration rates of MCF-7, SK-BR-3, and HCC-1937 cells to 10.58%, 13.22%, and 7.08%, respectively. The small molecule peptide tablets prepared in Example 2 can reduce the migration rates of MCF-7, SK-BR-3, and HCC-1937 cells to 4.14%, 9.95%, and 6.14%, respectively. The small molecule peptide tablets prepared in Example 3 can reduce the migration rates of MCF-7, SK-BR-3, and HCC-1937 cells to 22.96%, 30.86%, and 18.37%, respectively. The small molecule peptide tablets prepared in Example 4 can reduce the migration rates of MCF-7, SK-BR-3, and HCC-1937 cells to 9.20%, 14.21%, and 8.84%, respectively.
[0128] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that they can still modify or replace the technical solution of the present invention with equivalents, and these modifications or equivalent replacements cannot cause the modified technical solution to deviate from the spirit and scope of the technical solution of the present invention.
Claims
1. A method for preparing pumpkin seed protein-derived antioxidant and anticancer small molecule peptide tablets, characterized in that: The following steps are involved: S1. Pumpkin seed protein sequence acquisition: The pumpkin seed protein sequence was obtained from Uniprot; S2, submitting the pumpkin seed protein sequence obtained in step S1 to an online processing tool, selecting pepsin and trypsin to hydrolyze the pumpkin seed protein, and obtaining the active peptide sequence after gastrointestinal digestion; S3, using online databases to predict the safety of the peptide sequences obtained in S2; S4. Use molecular docking methods to screen active peptides with inhibitory potential on oxidative stress and breast cancer related targets; S5. Synthesis of small molecule peptides; S6. Preparation of small molecule peptide tablets.
2. The preparation method according to claim 1, characterized in that: In step S3, PeptideRanker, Toxinpred and Innovagen were used to predict the potential activity, toxicity, hydrophilicity, hydrophobicity, charge and solubility of the peptide sequences obtained in S2.
3. The preparation method according to claim 1-2, characterized in that: PeptideRanker is used to predict the potential activity of peptides; Toxinpred is used to predict the toxicity, hydrophobicity, hydrophilicity, and charge of peptides; Innovagen is used to predict the solubility of peptides.
4. The preparation method according to claim 1, characterized in that: In S4, the molecular docking method was used to screen active peptides with inhibitory potential on oxidative stress and breast cancer related targets, including the following steps: (1) Acquisition of 3D structures: The 3D structures of TP53, PHGDH, Caspase3, and Keap1 were obtained from the RCSB database; (2) Construction of active peptide structure: Use ChemDraw and Chem3D to construct active peptide structure; (3) Molecular docking: After removing the ligands and water molecules from TP53, PHGDH, Caspase3, and Keap1 in step (1), non-polar hydrogen and Gaussian charges were added together with the peptide sequence obtained in S2, and semi-flexible molecular docking of the peptide with TP53, the peptide with PHGDH, the peptide with Caspase3, and the peptide with Keap1 was performed using AutoDock 4.2 software; (4) After molecular docking, active peptides that showed the best binding to oxidative stress and breast cancer-related targets were screened based on the binding energy results.
5. The preparation method according to claim 4, characterized in that: The active peptides that showed the strongest binding to TP53 were YPSPPY, FPF, ISTANY, IIV, IPQN, VCPPL, CTAIR, VVPR, QPR, and IIPQN; The active peptides that showed the strongest binding to PHGDH were GIENPW, IIPQN, QGSEVW, GQQER, VNAPQL, MPHPCK, DDGSE, TPPPGY, QIVQR, and TIRPK; The active peptides that showed the strongest binding to Caspase3 were GVEEW, EW, EY, DDGSE, DF, EEA, NVGPE, EEL, DEEER, and PDIH; The active peptides that showed the strongest binding to Keap1 were YPSPPY, QIVQR, QGSEVW, VNAPQL, VQVVDN, IIPQN, QGQNDR, TPPPGY, TPPPGF, and GIENPW.
6. The preparation method according to claim 1, characterized in that: In S5, the active peptides screened in step S4 are synthesized into small molecule peptides using the Fmoc solid phase synthesis method.
7. The preparation method according to claim 1, characterized in that: S6 is a mixture of one or more of the small molecule peptides synthesized by S5, epigallocatechin gallate, ginsenoside, rutin, quercetin and dextrin.
8. The pumpkin seed protein-derived antioxidant and anticancer small molecule peptide tablets prepared by the preparation method according to any one of claims 1 to 7.
Citation Information
Patent Citations
Sheep milk whey protein immunoregulation peptide as well as compound and application thereof
CN108085357A
Composition of pumpkin seed protein and use thereof
WO2024055983A1
